Department of Pediatrics, Center for Academic Medicine, Pediatric Nephrology, Lucile Packard Children's Hospital, Stanford University, MC-5660, 453 Quarry Rd, Palo Alto, CA, 94304, USA.
Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, USA.
Pediatr Nephrol. 2025 Jan;40(1):253-264. doi: 10.1007/s00467-024-06438-x. Epub 2024 Aug 20.
Continuous kidney replacement therapy (CKRT) is often used for acute kidney injury (AKI) or fluid overload (FO) in children ≤ 10 kg. Intensive care unit (ICU) mortality in children ≤ 10 kg reported by the prospective pediatric CRRT (ppCRRT, 2001-2003) registry was 57%. We aimed to evaluate characteristics associated with ICU mortality using a contemporary registry.
The Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK) registry is a retrospective, multinational, observational study of children and young adults aged 0-25 years receiving CKRT (2015-2021) for AKI or FO. This analysis included patients ≤ 10 kg at hospital admission.
ICU mortality and major adverse kidney events at 90 days (MAKE-90) defined as death, persistent kidney dysfunction, or dialysis within 90 days, respectively.
A total of 210 patients were included (median age 0.53 years (IQR, 0.1, 0.9)). ICU mortality was 46.5%. MAKE-90 occurred in 150/207 (72%). CKRT was initiated at a median 3 days (IQR 1, 9) after ICU admission and lasted a median 6 days (IQR 3, 16). On multivariable analysis, pediatric logistic organ dysfunction score (PELOD-2) at CKRT initiation was associated with increased odds of ICU mortality (aOR 2.64, 95% CI 1.68-4.16), and increased odds of MAKE-90 (aOR 2.2, 95% CI 1.31-3.69). Absence of comorbidity was associated with lower MAKE-90 (aOR 0.29, 95%CI 0.13-0.65).
We report on a contemporary cohort of children ≤ 10 kg treated with CKRT for acute kidney injury and/or fluid overload. ICU mortality is decreased compared to ppCRRT. The extended risk of death and morbidity at 90 days highlights the importance of close follow-up.
连续肾脏替代疗法(CKRT)常用于儿童体重≤10 公斤的急性肾损伤(AKI)或液体超负荷(FO)。前瞻性儿科 CRRT(ppCRRT,2001-2003 年)登记处报告的儿童体重≤10 公斤的 ICU 死亡率为 57%。我们旨在使用当代登记处评估与 ICU 死亡率相关的特征。
全球肾脏病肾脏替代治疗探索协作组织(WE-ROCK)登记处是一项回顾性、多中心、观察性研究,纳入 2015-2021 年接受 CKRT 治疗 AKI 或 FO 的 0-25 岁儿童和青年患者。本分析包括入院时体重≤10 公斤的患者。
90 天内的 ICU 死亡率和主要不良肾脏事件(MAKE-90),定义分别为死亡、持续肾功能障碍或 90 天内透析。
共纳入 210 例患者(中位年龄 0.53 岁(IQR,0.1,0.9))。ICU 死亡率为 46.5%。MAKE-90 发生在 150/207(72%)例患者中。CKRT 在 ICU 入院后中位 3 天(IQR 1,9)开始,持续中位 6 天(IQR 3,16)。多变量分析显示,CKRT 开始时儿科逻辑器官功能障碍评分(PELOD-2)与 ICU 死亡率(OR 2.64,95%CI 1.68-4.16)和 MAKE-90(OR 2.2,95%CI 1.31-3.69)增加相关。无合并症与 MAKE-90 降低相关(OR 0.29,95%CI 0.13-0.65)。
我们报告了一个当代的儿童体重≤10 公斤的 CKRT 治疗急性肾损伤和/或液体超负荷的队列。与 ppCRRT 相比,ICU 死亡率降低。90 天的死亡和发病风险增加突出了密切随访的重要性。